Iovance Biotherapeutics Inc (IOVA)

NASD · Healthcare · Biotechnology · USA

Iovance Biotherapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

Iovance Biotherapeutics is a biopharmaceutical company developing tumor infiltrating lymphocyte cell therapies for solid tumor cancers. Its commercial products include Amtagvi, an individualized T cell therapy for previously treated advanced melanoma, and Proleukin, an interleukin-2 product used in treatment regimens. The company manufactures therapies at its Philadelphia facility and conducts clinical trials across various cancer types.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Iovance Biotherapeutics Inc stock.

Our verdict on IOVA

Not valued: We cannot value this company yet.

We do not publish a value for this company: its filings cover three fiscal years and projecting growth needs four in a row.

ETFs with the most weight in IOVA

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than IOVA in Biotechnology

129 more in this industry show a wider margin of safety.

Is IOVA undervalued or overvalued?

We do not publish a verdict on IOVA yet. A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover three fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.

What is the intrinsic value of IOVA?

We do not publish one (as of the 2026-11-17 close). A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover three fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.